Haemonetics Co. (NYSE:HAE) Stock Holdings Increased by Texas Permanent School Fund Corp

Texas Permanent School Fund Corp raised its holdings in shares of Haemonetics Co. (NYSE:HAE - Free Report) by 16.3% in the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 51,714 shares of the medical instruments supplier's stock after purchasing an additional 7,267 shares during the quarter. Texas Permanent School Fund Corp owned 0.10% of Haemonetics worth $4,278,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the business. Westfield Capital Management Co. LP grew its position in shares of Haemonetics by 27.2% during the fourth quarter. Westfield Capital Management Co. LP now owns 712,061 shares of the medical instruments supplier's stock worth $60,888,000 after buying an additional 152,098 shares in the last quarter. Goldman Sachs Group Inc. grew its holdings in Haemonetics by 14.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 191,253 shares of the medical instruments supplier's stock worth $16,354,000 after acquiring an additional 24,394 shares in the last quarter. Isthmus Partners LLC bought a new stake in shares of Haemonetics in the 4th quarter worth about $1,530,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Haemonetics in the 4th quarter worth about $888,000. Finally, Campbell & CO Investment Adviser LLC acquired a new stake in shares of Haemonetics in the 4th quarter valued at about $2,039,000. 99.67% of the stock is currently owned by hedge funds and other institutional investors.

Analyst Upgrades and Downgrades

HAE has been the subject of several research analyst reports. JMP Securities reissued a "market outperform" rating and issued a $125.00 price objective on shares of Haemonetics in a report on Tuesday, August 13th. Needham & Company LLC upgraded Haemonetics from a "hold" rating to a "buy" rating and set a $112.00 price target for the company in a report on Wednesday, June 12th. Bank of America began coverage on Haemonetics in a research note on Wednesday. They set a "neutral" rating and a $85.00 price objective on the stock. Citigroup lowered their target price on shares of Haemonetics from $94.00 to $85.00 and set a "neutral" rating for the company in a research note on Thursday, August 22nd. Finally, CL King initiated coverage on shares of Haemonetics in a research report on Friday. They issued a "buy" rating and a $116.00 price target on the stock. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. According to MarketBeat, Haemonetics has a consensus rating of "Moderate Buy" and an average price target of $106.14.

Insider Activity at Haemonetics

In related news, insider Stewart W. Strong sold 4,312 shares of the company's stock in a transaction dated Friday, July 26th. The shares were sold at an average price of $91.15, for a total value of $393,038.80. Following the completion of the sale, the insider now owns 18,196 shares of the company's stock, valued at $1,658,565.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Haemonetics news, EVP Anila Lingamneni sold 2,136 shares of the stock in a transaction on Thursday, July 11th. The stock was sold at an average price of $90.00, for a total transaction of $192,240.00. Following the completion of the transaction, the executive vice president now directly owns 21,410 shares of the company's stock, valued at approximately $1,926,900. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, insider Stewart W. Strong sold 4,312 shares of the business's stock in a transaction on Friday, July 26th. The stock was sold at an average price of $91.15, for a total value of $393,038.80. Following the completion of the sale, the insider now directly owns 18,196 shares in the company, valued at approximately $1,658,565.40. The disclosure for this sale can be found here. 1.80% of the stock is owned by insiders.

Haemonetics Stock Performance

Shares of HAE traded up $2.83 during midday trading on Friday, hitting $76.09. 670,561 shares of the stock traded hands, compared to its average volume of 535,663. The company has a debt-to-equity ratio of 1.35, a quick ratio of 2.33 and a current ratio of 3.76. Haemonetics Co. has a 1-year low of $70.74 and a 1-year high of $97.97. The business's 50 day moving average price is $81.38 and its two-hundred day moving average price is $83.89. The firm has a market capitalization of $3.89 billion, a PE ratio of 33.23, a price-to-earnings-growth ratio of 1.32 and a beta of 0.30.

Haemonetics (NYSE:HAE - Get Free Report) last posted its earnings results on Thursday, August 8th. The medical instruments supplier reported $1.02 EPS for the quarter, missing the consensus estimate of $1.03 by ($0.01). The firm had revenue of $336.17 million during the quarter, compared to the consensus estimate of $335.08 million. Haemonetics had a return on equity of 21.86% and a net margin of 8.61%. Haemonetics's revenue for the quarter was up 8.0% on a year-over-year basis. During the same quarter last year, the company posted $1.05 EPS. Equities research analysts predict that Haemonetics Co. will post 4.58 EPS for the current fiscal year.

Haemonetics Profile

Haemonetics Corporation, a healthcare company, provides suite of medical products and solutions in the United States and internationally. The company offers automated plasma collection systems, donor management software, and supporting software solutions including NexSys PCS and PCS2 plasmapheresis equipment and related disposables and solutions, as well as integrated information technology platforms for plasma customers to manage their donors, operations, and supply chain; and NexLynk DMS donor management system and Donor360 app.